1Leung AY,Yuen KY,Kwong YL.Polyoma BK virus and hemorrhagic cystitis in hematopoietic stem cell transplantation:a changing paradigm[].Bone Marrow Transplantation.2005
2Liu YT.A serological study on anti-CMV and anti-EBV antibodies in population of Beijing,Changzhi Shanxi and Yichang Hubei[].Chinese Journal of Pharmaco Epidemiology.1989
3Cox,PJ.Cyclophosphamide cystitis-Identification of acrolein as the causative agent[].Biochemical Pharmacology.1979
4Russell SJ,Vowels MR,Vale T.Hemorrhagic cystitis in pediatric bone marrow transplant patients: an association with infective agents, GVHD and prior cyclophosphamide[].Bone Marrow Transplantation.1994
5Bedi A,Miller CB,Hanson JL, et al.Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation[].Journal of Clinical Oncology.1995
6Akiyama H,Kurosu T,Sakashita C,et al.Adenovirus is a key pathogen in hemorrhagic cystitis associated with bone marrow transplantation[].Clinical Infectious Diseases.2001
7Daopei L U.Bone marrow transplantation in the People′s Republic of China[].Bone Marrow Transplantation.1994
8Sencer SF,,Haake RJ,Weisdorf DJ.Hemorrhagic cystitis after Bone Marrow transplantation. Risk factor and complications[].Transplantation.1993
9Leung AY,Mak R,Lie AK,Yuen KY,Cheng VC,Liang R,Kwong YL.Clinicopathological features and risk factors of clinically overt haemorrhagic cystitis complicating bone marrow transplantation[].Bone Marrow Transplantation.2002
10Bogdanovic G,Ljungman P,Wang F,et al.Presence of human polyomavirus DNA in the peripheral circulation of bone marrow transplant patients with and without hemorrhagic cystitis[].Bone Marrow Transplantation.1996
2Borowitz M, Bene MC, Harris NL, et al. Acute leukemias of ambiguous lineage[M]//Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumors: pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon, IARC Press, 2008: 150-155.
3Brüggemann M, Schrauder A, Raff T, et al. Standardized MRD quantification in European ALL trials: proceedings of the second international symposium on MRD assessment in Kiel, Germany, 18–20 September 2008[J]. Leukemia, 2010, 24 (3): 521-535.
4Pedreira CE, Costa ES, Barrena S, et al. Generation of flow cytometry data files with a potentially infinite number of dimensions[J]. Cytometry A, 2008, 73 (9): 834-846.
5Weinberg OK, Arber DA. Mixed-phenotype acute leukemia: historical overview and a new definition[J]. Leukemia, 2010, 24(11): 1844-1851.
6Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms[J]. Blood, 2008, 111(8): 3941-3967.
7Matutes E, Pickl WF, van’t VeerM, et al. Mixed-phenotype acute leukemia: clinical and laboratory features and classification outcome in 100 patients defined according to the WHO 2008[J]. Blood, 2011, 117(11): 3163-3171.
8van den Ancker W, Terwijn M, Westers TM, et al. Acute leukemias of ambiguous lineage: diagnostic consequences of the WHO 2008 classification [J]. Leukemia, 2010, 24(7): 1392-1396.
9Wood B. 9-color and 10-color flow cytometry in the clinical laboratory[J]. Arch Pathol Lab Med, 2006, 130(5): 680-690.
10Preffer F, Dombkowski D. Advances in complex multiparameter flow cytometry technology: applications in stem cell research[J]. Cytometry B Clin Cytom, 2009, 76(5): 295-314.
